

Title (en)

Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders

Title (de)

Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen

Title (fr)

Composition pharmaceutique utiles pour le traitement de troubles du SNC ou d'autres troubles

Publication

EP 1231212 B1 20061220 (EN)

Application

EP 02250540 A 20020128

Priority

- US 26674901 P 20010206
- US 27499401 P 20010312

Abstract (en)

[origin: EP1231212A1] The present invention relates to a method of treating disorders of the central nervous system (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant alpha 7 nicotinic receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant alpha 7 nicotinic receptor agonist.

IPC 8 full level

C07D 471/08 (2006.01); **A61K 31/00** (2006.01); **A61K 31/551** (2006.01); **A61K 31/69** (2006.01); **A61P 1/04** (2006.01); **A61P 3/04** (2006.01); **A61P 5/38** (2006.01); **A61P 9/00** (2006.01); **A61P 9/06** (2006.01); **A61P 9/08** (2006.01); **A61P 9/12** (2006.01); **A61P 21/04** (2006.01); **A61P 25/00** (2006.01); **A61P 25/02** (2006.01); **A61P 25/04** (2006.01); **A61P 25/06** (2006.01); **A61P 25/08** (2006.01); **A61P 25/10** (2006.01); **A61P 25/12** (2006.01); **A61P 25/14** (2006.01); **A61P 25/16** (2006.01); **A61P 25/18** (2006.01); **A61P 25/20** (2006.01); **A61P 25/22** (2006.01); **A61P 25/24** (2006.01); **A61P 25/28** (2006.01); **A61P 25/30** (2006.01); **A61P 25/32** (2006.01); **A61P 25/34** (2006.01); **A61P 25/36** (2006.01); **A61P 31/18** (2006.01); **C07D 213/30** (2006.01); **C07D 487/08** (2006.01); **C07D 519/00** (2006.01); **C07D 521/00** (2006.01)

CPC (source: EP US)

A61P 1/04 (2017.12 - EP); **A61P 3/04** (2017.12 - EP); **A61P 5/38** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/06** (2017.12 - EP); **A61P 9/08** (2017.12 - EP); **A61P 9/12** (2017.12 - EP); **A61P 21/04** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/02** (2017.12 - EP); **A61P 25/04** (2017.12 - EP); **A61P 25/06** (2017.12 - EP); **A61P 25/08** (2017.12 - EP); **A61P 25/10** (2017.12 - EP); **A61P 25/12** (2017.12 - EP); **A61P 25/14** (2017.12 - EP); **A61P 25/16** (2017.12 - EP); **A61P 25/18** (2017.12 - EP); **A61P 25/20** (2017.12 - EP); **A61P 25/22** (2017.12 - EP); **A61P 25/24** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 25/30** (2017.12 - EP); **A61P 25/32** (2017.12 - EP); **A61P 25/34** (2017.12 - EP); **A61P 25/36** (2017.12 - EP); **A61P 31/18** (2017.12 - EP); **C07D 213/30** (2013.01 - EP US); **C07D 231/12** (2013.01 - EP US); **C07D 233/56** (2013.01 - EP US); **C07D 249/08** (2013.01 - EP US); **C07D 471/08** (2013.01 - EP US)

Cited by

WO2007135122A1; WO2007135120A1; CN100445285C; AU2016244305B2; FR2931823A1; FR2931677A1; RU2493851C2; AU2009264016B2; IT201700059292A1; WO2009112462A2; WO2013002365A1; WO2005061511A1; WO2005061510A1; WO2009156678A3; WO2009112462A3; WO2009109517A1; US7678788B2; EP2255848A2; US10913751B2; US7176201B2; US8003693B2; WO2009156678A2; US8569289B2; US11008316B2; WO2004076453A1; EP1987033B1; JP2006511484A; WO2009156680A3; WO2018220542A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

EP 1231212 A1 20020814; EP 1231212 B1 20061220; AT E348829 T1 20070115; BR 0200283 A 20021008; CA 2370411 A1 20020806; CA 2370411 C 20060110; DE 60216830 D1 20070201; DE 60216830 T2 20070614; ES 2275808 T3 20070616; JP 2002302490 A 20021018; MX PA02001306 A 20040622; US 2002177591 A1 20021128; US 2006014750 A1 20060119

DOCDB simple family (application)

EP 02250540 A 20020128; AT 02250540 T 20020128; BR 0200283 A 20020205; CA 2370411 A 20020204; DE 60216830 T 20020128; ES 02250540 T 20020128; JP 2002029074 A 20020206; MX PA02001306 A 20020204; US 22844905 A 20050915; US 6869202 A 20020206